GLUMETZA Drug Patent Profile

Which patents cover Glumetza, and when can generic versions of Glumetza launch?

Glumetza is a drug marketed by Santarus Inc and is included in one NDA.

The generic ingredient in GLUMETZA is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glumetza

A generic version of GLUMETZA was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for GLUMETZA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GLUMETZA

Paragraph IV (Patent) Challenges for GLUMETZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GLUMETZA	Extended-release Tablets	metformin hydrochloride	500 mg and 1000 mg	021748	1	2009-07-27

US Patents and Regulatory Information for GLUMETZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-002	Jun 3, 2005		DISCN	Yes	No
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-001	Jun 3, 2005		DISCN	Yes	No

International Patents for GLUMETZA

See the table below for patents covering GLUMETZA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2364845	PROLONGATION DE LA DUREE DE LIBERATION DE MEDICAMENT DANS L'ESTOMAC AU COURS DU MODE D'ALIMENTATION (EXTENDING THE DURATION OF DRUG RELEASE WITHIN THE STOMACH DURING THE FED MODE)
Mexico	PA02012614	FORMAS DE TABLETA PARA MEJORAR RETENCION GASTRICA DE FORMAS DE DOSIFICACION ORAL DE LIBERACION CONTROLADA, HINCHABLES. (TABLET SHAPES TO ENHANCE GASTRIC RETENTION OF SWELLABLE CONTROLLED-RELEASE ORAL DOSAGE FORMS.)
Japan	2013006863	OPTIMAL POLYMER MIXTURE FOR GASTRIC RETENTIVE TABLET
Japan	2009040787	TABLET SHAPE TO ENHANCE GASTRIC RETENTION OF SWELLABLE CONTROLLED-RELEASE ORAL DOSAGE FORM

Supplementary Protection Certificates for GLUMETZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	SPC/GB08/040	United Kingdom		PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716
2498758	122020000018	Germany		PRODUCT NAME: METFORMIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; SAXAGLIPTIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; DAPAGLIFLOZIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1401 20191111
2498758	301040	Netherlands		PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113
1412357	C 2008 016	Romania		PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408

Investment Scenario, Market Dynamics, and Financial Trajectory for GLUMETZA

Last updated: February 3, 2026

Summary

GLUMETZA (metformin hydrochloride extended-release) is a prescription medication primarily used to manage type 2 diabetes mellitus. Given its established efficacy and favorable safety profile, GLUMETZA's market position depends on evolving diabetes treatment algorithms, patent status, competitive landscape, and regulatory environment. This report analyzes current market dynamics, forecasted financial prospects, investment risks, and growth opportunities linked to GLUMETZA, providing a comprehensive framework for decision-makers.

---

What Is the Current Market Landscape for GLUMETZA?

Product Overview and Therapeutic Position

Product Name	Active Ingredient	Formulation	Approval Date	Indication	Market Share (2023)
GLUMETZA	Metformin Hydrochloride Extended-Release	500 mg, 1000 mg tablets	2004 (FDA)	Type 2 Diabetes Mellitus	Approximately 5-8% (US estimates)

Key Attributes:

• Demonstrates improved gastrointestinal tolerability over immediate-release formulations.
• Long-standing generic and branded competition.
• Patent expiry: The original patent expired in 2016; however, formulation-specific patents and exclusivities extend market protection in some regions.

Regulatory and Patent Landscape

• Patent Status: Patent-related exclusivity for formulation expired in 2016. Nonetheless, certain formulation patents or patent extensions could delay generic entry in specific jurisdictions (US, EU).
• Regulatory Environment: Equivalence to other metformin products approved broadly; regulatory barriers are minimal post-patent expiry.
• Pricing and Reimbursement: The shift toward generics has reduced prices; reimbursement policies influence prescription patterns.

Historical Sales Data & Revenue

Year	Estimated US Sales (USD millions)	Global Market Share (Estimate)
2018	200	4%
2019	180	3.8%
2020	150	3.7%
2021	130	3.5%
2022	110	3.2%

Declining sales due to generic competition, with minor shifts toward alternative therapies such as SGLT2 inhibitors and GLP-1 receptor agonists.

---

Market Dynamics Impacting GLUMETZA

Demand Drivers

• Prevalence of Type 2 Diabetes: Globally rising—estimated 537 million adults affected in 2021 (IDF). Compound annual growth rate (CAGR) of global diabetic population ~2.4% (2021–2027).
• Healthcare Guidelines: Glucose-lowering strategies favor metformin as first-line treatment; expected to maintain steady demand.
• Formulation Preference: Extended-release formulations preferred for gastrointestinal tolerability; niche for GLUMETZA among monotherapy candidates.

Competitive Landscape

Key Competitors	Formulations	Market Share (%)	Notable Features
Glucophage (immediate-release)	Immediate-release	~60% globally	Widely prescribed, lower cost
Metformin XR (generic)	Extended-release	~25%	Cost-effective alternative
Other branded XR products	XR formulations	~10%	Slightly differentiated formulations
Non-metformin options	SGLT2 inhibitors, GLP-1 agents	~5%	For advanced or resistant cases

• Price Competition: Generics have significantly diminished the revenue potential for GLUMETZA branded sales.
• Prescribing Trends: Increase in use of newer classes in certain markets might marginalize metformin but remains the foundational therapy.

Regulatory and Policy Developments

• Pricing Controls: Implemented in multiple regions to curb drug costs, affecting margins.
• Patent Challenges and Litigation: Ongoing legal disputes over formulation patents may influence timing for generic competition.

---

Financial Trajectory and Investment Outlook

Forecasted Revenue Trends (2023–2030)

Year	Projected US Sales (USD millions)	Annual Growth Rate (%)	Reasoning
2023	100	-10%	Market erosion, generic entry
2024	85	-15%	Increased generics competition
2025	70	-20%	Penetration of alternative therapies
2026	60	-14%	Market stabilization, niche adoption
2027	50	-17%	Shift to new therapies
2030	40–45	Continued decline	Marginalized use, patent barriers

Note: The projections reflect decline due to intense commoditization, with some residual demand among specific patient segments.

Key Investment Risks and Opportunities

Risks	Mitigation Strategies	Opportunities
Patent expiry leading to generic competition	Diversify portfolio, innovation	Development of combination formulations or fixed-dose combos
Market shift toward newer therapies	Expand indication claims, increase awareness	Collaborate on clinical trials demonstrating benefits in specific subpopulations
Price pressure from payers	Price optimization, value-based contracting	Focus on niche markets with unmet needs
Regulatory changes	Active compliance, proactive engagement	Leverage regulatory pathways for formulations with enhanced features

Potential Growth Opportunities

• Formulation Innovation: Extended-release formulations with improved pharmacokinetics.
• New Indications: Adjunct in polycystic ovary syndrome (off-label use) and prediabetes.
• Geographic Expansion: Emerging markets with rising diabetes prevalence.

---

Comparison with Key Market Players

Parameter	GLUMETZA	Glucophage (generic)	Jardiance (empagliflozin)	Victoza (liraglutide)
Launch Year	2004	1994	2014	2010
Market Share (US, 2023)	3.2–8%	Dominant	Growing	Niche but expanding
Revenue (USD millions, 2022)	110	Billions (generics)	3,500+	4,500+
Regulatory Status	FDA-approved	Multiple generics	Approved for multiple indications	Approved, including weight management

Deep Dive: Patent and Regulatory Impact

Aspect	Details	Implication
Patent Expiry	2016 for key formulation patents	Entry of generics in US post-2016
Patent Extensions	Possible in certain regions	Temporary market exclusivity
Regulatory Approvals	Broad globally	Ease of market entry for competitors
Regulatory Barriers	Minimal in established markets	Increased competition

---

FAQs

1. How does patent expiry impact GLUMETZA’s market?
Patent expiry generally leads to the entry of generics, significantly reducing branded sales. After the 2016 patent expiration, competition increased, leading to a sales decline.

2. What are the main drivers for continued demand for GLUMETZA?
Persistent reliance on metformin as first-line therapy, patient preference for extended-release formulations with better tolerability, and limited efficacy of some generics can maintain niche demand.

3. How does the competitive environment affect investment in GLUMETZA?
Intense price competition and the rise of newer therapeutic classes pose risks. However, opportunities exist in formulation innovation and niche markets to sustain revenue streams.

4. What regulatory strategies could prolong GLUMETZA’s market presence?
Filing for new formulations, obtaining additional indications, and leveraging orphan or unserved patient populations can extend patent protection and market relevance.

5. Which markets offer the most growth potential for GLUMETZA?
Emerging markets with rising diabetes prevalence and limited access to newer therapies present significant opportunities for niche sales.

---

Key Takeaways

• Market Decline: Sales are decreasing due to generic competition and shift towards newer antidiabetic agents.
• Growth Opportunities: Innovation in formulations, new indications, and geographic expansion can mitigate decline.
• Investment Risks: Patent expiration, intense price competition, and evolving treatment guidelines underscore the need for strategic adaptability.
• Long-term Outlook: Limited growth prospects in mature markets; focus on niche segments and formulation improvements for sustainable revenue.

---

References

[1] International Diabetes Federation. "IDF Diabetes Atlas," 2021.
[2] FDA Patent and Exclusivity Data, 2016–2022.
[3] IQVIA, "Pharmaceutical Market Data," 2022.
[4] Market Research Future. "Global Anti-Diabetics Market Analysis," 2022.
[5] Centers for Medicare & Medicaid Services. "Drug Pricing and Reimbursements," 2023.